Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Crivellari

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1995
Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG)D Crivellari, K N Price, M Hagen, et al.
International Journal of Cancer|August 17, 1999
BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in ItalyM Santarosa, R Dolcetti, M D Magri, et al.
Future Oncology (London, England)|February 25, 2015
Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patientsG Mustacchi, F Puglisi, A M Molino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxelD Crivellari, O Pagani, A Veronesi, et al.
International Journal of Cancer|November 10, 1998
Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancerM Santarosa, A Viel, R Dolcetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II studyO Pagani, C Sessa, F Nolè, et al.
Tumori|December 31, 1982
Carcinoembryonic antigen (CEA) in the follow-up of disease-free breast cancer patientsA Veronesi, R Talamini, S Longhi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancerO Pagani, C Sessa, G Martinelli, et al.
Journal of Translational Medicine|June 28, 2015
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapyE Muraro, E Comaro, R Talamini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancerS Gori, F Montemurro, S Spazzapan, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1995
Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG)D Crivellari, K N Price, M Hagen, et al.
International Journal of Cancer|August 17, 1999
BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in ItalyM Santarosa, R Dolcetti, M D Magri, et al.
Future Oncology (London, England)|February 25, 2015
Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patientsG Mustacchi, F Puglisi, A M Molino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxelD Crivellari, O Pagani, A Veronesi, et al.
International Journal of Cancer|November 10, 1998
Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancerM Santarosa, A Viel, R Dolcetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II studyO Pagani, C Sessa, F Nolè, et al.
Tumori|December 31, 1982
Carcinoembryonic antigen (CEA) in the follow-up of disease-free breast cancer patientsA Veronesi, R Talamini, S Longhi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancerO Pagani, C Sessa, G Martinelli, et al.
Journal of Translational Medicine|June 28, 2015
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapyE Muraro, E Comaro, R Talamini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancerS Gori, F Montemurro, S Spazzapan, et al.
Pageof 9